Biomarker may predict who'll benefit from targeted therapy for HER2-negative breast cancer

(Case Western Reserve University) A multi-center team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond -- and which should switch to another kind of treatment. Their findings appear in this month's International Journal of Cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news